REGN Competition Analysis

Regeneron Pharmaceuticals, Inc. Peer Comparison

Metric	Value	Ranking
Market Cap	$76.0 Billion	2/21	NVO $380.4B	REGN $76.0B	ALNY $32.4B	BGNE $20.2B	UTHR $16.1B	INCY $14.0B	BMRN $11.7B	SRPT $11.4B	RXDX $9.6B	IMGN $8.7B	RETA $6.6B	MDGL $6.0B	IONS $5.2B	KRYS $4.2B	RARE $3.8B	APLS $3.6B	CRSP $3.3B	PTCT $3.3B	ARWR $2.4B	NTLA $989.0M	ICPT $794.7M
Gross Margin	94%	8/21	ICPT 100%	NTLA 100%	RXDX 100%	ALNY 99%	IMGN 98%	MDGL 97%	RETA 96%	REGN 94%	INCY 92%	PTCT 92%	KRYS 90%	UTHR 89%	RARE 85%	NVO 84%	BGNE 83%	APLS 81%	SRPT 80%	BMRN 74%	IONS 39%	ARWR 0%	CRSP -100%
Profit Margin	36%	4/21	RETA 100%	UTHR 41%	NVO 38%	REGN 36%	KRYS 32%	IMGN 27%	BMRN 14%	INCY 9%	SRPT 7%	ARWR 0%	ICPT -3%	BGNE -12%	ALNY -27%	APLS -33%	PTCT -79%	RARE -96%	IONS -100%	MDGL -100%	NTLA -100%	CRSP -100%	RXDX -100%
EBITDA margin	32%	3/21	UTHR 56%	NVO 52%	REGN 32%	IMGN 27%	KRYS 27%	BMRN 16%	INCY 16%	SRPT 5%	ICPT -3%	BGNE -5%	ALNY -18%	APLS -38%	PTCT -40%	RARE -95%	ARWR -100%	MDGL -166%	IONS -196%	RETA -356%	NTLA -1490%	RXDX -4408%	CRSP -18294%
Quarterly Revenue	$3.7 Billion	3/21	BMRN $733.9B	NVO $10.5B	REGN $3.7B	INCY $1.1B	BGNE $1.0B	UTHR $748.9M	SRPT $467.2M	ALNY $420.1M	APLS $176.6M	RARE $139.5M	PTCT $135.4M	IMGN $113.4M	ICPT $88.8M	KRYS $83.8M	IONS $75.7M	MDGL $62.2M	RETA $22.7M	NTLA $9.1M	RXDX $1.1M	CRSP $602,000	ARWR $0
Quarterly Earnings	$1.3 Billion	3/21	BMRN $106.1B	NVO $4.0B	REGN $1.3B	UTHR $309.1M	RETA $193.0M	INCY $106.5M	SRPT $33.6M	IMGN $30.7M	KRYS $27.2M	ICPT -$2.8M	RXDX -$33.0M	APLS -$57.4M	CRSP -$85.9M	PTCT -$106.7M	MDGL -$107.0M	ALNY -$111.6M	BGNE -$121.4M	RARE -$133.5M	NTLA -$135.7M	IONS -$140.5M	ARWR -$170.5M
Quarterly Free Cash Flow	$1.1 Billion	3/21	BMRN $321.2B	NVO $4.6B	REGN $1.1B	UTHR $300.7M	INCY $293.2M	KRYS $57.8M	BGNE $54.7M	ALNY $39.5M	APLS $34.1M	ICPT $3.9M	IMGN $1.4M	PTCT -$22.8M	RXDX -$40.1M	RARE -$56.1M	MDGL -$62.8M	RETA -$70.2M	NTLA -$86.1M	SRPT -$98.0M	CRSP -$107.1M	IONS -$108.8M	ARWR -$161.5M
Trailing 4 Quarters Revenue	$13.8 Billion	3/21	BMRN $1.4T	NVO $39.9B	REGN $13.8B	INCY $4.1B	BGNE $3.3B	UTHR $2.8B	ALNY $2.0B	SRPT $1.6B	PTCT $839.3M	IONS $744.7M	APLS $675.9M	RARE $522.7M	IMGN $329.6M	ICPT $317.7M	KRYS $241.5M	CRSP $201.6M	MDGL $76.8M	NTLA $43.1M	RETA $24.4M	RXDX $4.0M	ARWR $3.6M
Trailing 4 Quarters Earnings	$4.7 Billion	3/21	BMRN $733.9B	NVO $10.5B	REGN $3.7B	INCY $1.1B	BGNE $1.0B	UTHR $748.9M	SRPT $467.2M	ALNY $420.1M	APLS $176.6M	RARE $139.5M	PTCT $135.4M	IMGN $113.4M	ICPT $88.8M	KRYS $83.8M	IONS $75.7M	MDGL $62.2M	RETA $22.7M	NTLA $9.1M	RXDX $1.1M	CRSP $602,000	ARWR -$0
Quarterly Earnings Growth	33%	7/21	BMRN 262617%	RETA 362%	SRPT 182%	KRYS 182%	IMGN 175%	APLS 59%	REGN 33%	CRSP 23%	NVO 21%	PTCT 20%	RARE 16%	UTHR 16%	IONS 4%	RXDX -3%	MDGL -8%	NTLA -11%	INCY -38%	ARWR -55%	ICPT -101%	BGNE -156%	ALNY -176%
Annual Earnings Growth	19%	9/21	SRPT 208%	KRYS 133%	IMGN 92%	RETA 72%	ALNY 51%	APLS 51%	PTCT 38%	CRSP 31%	REGN 19%	NVO 17%	RARE 13%	IONS 11%	BGNE 7%	UTHR 6%	NTLA -6%	RXDX -15%	BMRN -25%	ARWR -43%	MDGL -46%	INCY -96%	ICPT -124%
Quarterly Revenue Growth	11%	12/21	BMRN 126140%	RETA 2885%	IMGN 127%	APLS 78%	RARE 42%	SRPT 41%	BGNE 28%	INCY 24%	UTHR 23%	NVO 21%	ICPT 14%	REGN 11%	MDGL 0%	CRSP 0%	KRYS 0%	NTLA -24%	PTCT -31%	ALNY -44%	IONS -47%	RXDX -72%	ARWR -100%
Annual Revenue Growth	8%	11/21	RETA 596%	IMGN 90%	APLS 76%	SRPT 47%	RXDX 32%	BGNE 29%	RARE 24%	NVO 22%	ALNY 18%	UTHR 15%	REGN 8%	INCY 8%	ICPT 8%	IONS 5%	MDGL 0%	PTCT 0%	KRYS 0%	CRSP -4%	NTLA -18%	BMRN -23%	ARWR -94%
Cash On Hand	$2.0 Billion	4/21	BMRN $675.4B	NVO $8.4B	BGNE $2.7B	REGN $2.0B	UTHR $1.6B	INCY $1.3B	ALNY $1.1B	IMGN $605.5M	PTCT $526.0M	APLS $396.9M	KRYS $374.0M	IONS $334.6M	MDGL $232.7M	CRSP $225.7M	SRPT $197.9M	RARE $150.6M	NTLA $120.5M	RXDX $113.3M	ICPT $102.7M	ARWR $102.7M	RETA $48.8M
Short Term Debt	$0	19/21	BGNE $881.5M	NVO $814.2M	UTHR $400.0M	SRPT $91.6M	IONS $44.0M	ALNY $42.1M	NTLA $19.2M	CRSP $16.9M	PTCT $16.8M	BMRN $15.6M	RARE $10.4M	APLS $6.8M	ARWR $6.3M	INCY $3.9M	RXDX $3.5M	RETA $2.5M	KRYS $1.3M	MDGL $878,000	REGN -$0	ICPT -$0	IMGN -$24.9M
Long Term Debt	$2.7 Billion	3/21	BMRN $594.6B	NVO $7.6B	REGN $2.7B	IONS $1.4B	SRPT $1.3B	ALNY $1.3B	RARE $829.7M	ARWR $504.2M	PTCT $383.5M	ICPT $223.9M	BGNE $220.0M	CRSP $210.7M	RETA $163.5M	MDGL $118.3M	APLS $104.7M	NTLA $82.4M	IMGN $72.1M	INCY $28.2M	RXDX $26.0M	UTHR $0	KRYS $0
PE	16.33	5/21	INCY 429.76	SRPT 93.55	KRYS 80.42	NVO 27.23	REGN 16.33	UTHR 14.53	BMRN 0.09	IMGN -1.00	ALNY -1.00	IONS -1.00	BGNE -1.00	RETA -1.00	ARWR -1.00	ICPT -1.00	RARE -1.00	MDGL -1.00	PTCT -1.00	NTLA -1.00	CRSP -1.00	APLS -1.00	RXDX -1.00
PS	5.49	16/21	RXDX 2392.62	ARWR 663.34	RETA 269.17	MDGL 77.92	NVO 64.63	IMGN 26.48	NTLA 22.95	KRYS 17.44	CRSP 16.53	ALNY 16.08	RARE 7.24	IONS 7.04	SRPT 6.95	BGNE 6.09	UTHR 5.86	REGN 5.49	APLS 5.34	PTCT 3.88	INCY 3.42	ICPT 2.50	BMRN 0.01
PB	2.59	17/21	ALNY 1000.67	RETA 75.22	NVO 21.40	IMGN 15.54	APLS 15.23	RXDX 13.70	ARWR 12.33	ICPT 11.06	RARE 10.70	SRPT 9.33	IONS 7.92	MDGL 7.70	BGNE 5.88	KRYS 4.75	INCY 4.40	UTHR 2.65	REGN 2.59	CRSP 1.72	NTLA 1.03	BMRN 0.00	PTCT 0.00
PC	37.79	5/21	RETA 134.44	RXDX 84.33	SRPT 57.61	NVO 45.24	REGN 37.79	ALNY 29.43	MDGL 25.72	RARE 25.12	ARWR 22.94	IONS 15.67	CRSP 14.77	IMGN 14.41	KRYS 11.26	INCY 10.70	UTHR 10.39	APLS 9.10	NTLA 8.21	ICPT 7.74	BGNE 7.48	PTCT 6.20	BMRN 0.02
Liabilities to Equity	0.28	14/21	ALNY 128.97	ARWR 5.12	RETA 4.76	ICPT 4.47	IONS 3.65	RARE 3.42	APLS 2.80	NVO 2.30	SRPT 1.95	BGNE 0.70	INCY 0.58	IMGN 0.46	MDGL 0.38	REGN 0.28	BMRN 0.27	NTLA 0.22	UTHR 0.17	CRSP 0.16	KRYS 0.11	RXDX 0.09	PTCT 0.00
ROA	0.12	2/21	UTHR 16%	REGN 12%	KRYS 5%	NVO 4%	SRPT 3%	BMRN 2%	INCY 1%	IMGN -2%	ALNY -8%	CRSP -11%	IONS -12%	BGNE -15%	ICPT -15%	RETA -16%	RXDX -19%	PTCT -25%	APLS -28%	RARE -36%	NTLA -45%	MDGL -48%	ARWR -53%
ROE	0.16	3/21	PTCT 43%	UTHR 18%	REGN 16%	NVO 12%	SRPT 10%	KRYS 6%	BMRN 2%	INCY 1%	IMGN -3%	CRSP -12%	RXDX -20%	BGNE -25%	IONS -54%	NTLA -54%	MDGL -67%	ICPT -82%	RETA -94%	APLS -105%	RARE -161%	ARWR -323%	ALNY -1027%
Current Ratio	4.61	7/21	RXDX 12.47	KRYS 10.18	CRSP 7.13	UTHR 6.97	NTLA 5.57	BMRN 4.77	REGN 4.61	MDGL 3.62	IMGN 3.16	INCY 2.72	BGNE 2.43	SRPT 1.51	NVO 1.44	APLS 1.36	RARE 1.30	IONS 1.27	ICPT 1.22	RETA 1.21	ARWR 1.20	ALNY 1.01	PTCT 0.64
Quick Ratio	1.21	8/21	INCY 429.76	SRPT 93.55	KRYS 80.42	NVO 27.23	REGN 16.33	UTHR 14.53	BMRN 0.09	IMGN -1.00	ALNY -1.00	IONS -1.00	BGNE -1.00	RETA -1.00	ARWR -1.00	ICPT -1.00	RARE -1.00	MDGL -1.00	PTCT -1.00	NTLA -1.00	CRSP -1.00	APLS -1.00	RXDX -1.00
Long Term Debt to Equity	0.09	14/21	ALNY} 38.93	ICPT} 3.12	ARWR} 2.72	RARE} 2.39	IONS} 2.18	RETA} 1.87	SRPT} 1.07	APLS} 0.44	NVO} 0.43	MDGL} 0.15	IMGN} 0.13	BMRN} 0.11	CRSP} 0.11	REGN} 0.09	NTLA} 0.09	BGNE} 0.06	RXDX} 0.04	INCY} 0.01	UTHR} 0.00	KRYS} 0.00	PTCT} -0.36
Debt to Equity	0.09	14/21	ALNY 40.24	ICPT 3.12	ARWR 2.75	IONS 2.18	RETA 1.90	SRPT 1.14	NVO 0.47	APLS 0.47	BGNE 0.32	IMGN 0.13	CRSP 0.12	BMRN 0.11	NTLA 0.11	REGN 0.09	UTHR 0.07	RXDX 0.04	RARE 0.03	INCY 0.01	MDGL 0.00	KRYS 0.00	PTCT -0.38
Burn Rate	-1.63	15/21	ICPT 8.75	BGNE 7.71	ALNY 6.38	APLS 6.27	SRPT 4.76	PTCT 4.17	RXDX 3.24	CRSP 2.29	MDGL 2.08	IONS 1.60	RARE 0.89	NTLA 0.84	ARWR 0.53	RETA -0.26	REGN -1.63	UTHR -7.43	BMRN -8.21	INCY -12.50	KRYS -13.92	IMGN -17.77	NVO -96.87
Cash to Cap	0.03	16/21	BMRN 57.55	PTCT 0.16	BGNE 0.13	ICPT 0.13	NTLA 0.12	APLS 0.11	UTHR 0.10	INCY 0.09	KRYS 0.09	IMGN 0.07	CRSP 0.07	IONS 0.06	ARWR 0.04	RARE 0.04	MDGL 0.04	REGN 0.03	ALNY 0.03	NVO 0.02	SRPT 0.02	RETA 0.01	RXDX 0.01
CCR	0.83	9/21	BMRN 3.03	INCY 2.75	KRYS 2.13	CRSP 1.25	RXDX 1.21	NVO 1.15	UTHR 0.97	ARWR 0.95	REGN 0.83	IONS 0.77	NTLA 0.63	MDGL 0.59	RARE 0.42	PTCT 0.21	IMGN 0.05	ALNY -0.35	RETA -0.36	BGNE -0.45	APLS -0.59	ICPT -1.38	SRPT -2.91
EV to EBITDA	65.04	5/21	SRPT} 567.58	IMGN} 267.45	KRYS} 171.13	INCY} 70.56	REGN} 65.04	UTHR} 35.88	NVO} 1.50	BMRN} -0.61	NTLA} -7.15	ARWR} -18.05	RARE} -27.61	CRSP} -30.27	IONS} -42.76	APLS} -49.24	MDGL} -55.86	PTCT} -57.50	RETA} -82.50	RXDX} -194.54	ICPT} -331.82	BGNE} -379.98	ALNY} -423.61
EV to Revenue	5.54	14/21	RXDX 2371.62	ARWR 778.20	RETA 273.97	MDGL 74.90	IMGN 24.86	NTLA 22.52	CRSP 16.54	ALNY 16.18	KRYS 15.90	IONS 8.53	SRPT 7.68	RARE 6.97	BGNE 5.61	REGN 5.54	UTHR 5.44	APLS 4.92	PTCT 3.73	INCY 3.11	ICPT 2.88	NVO 1.40	BMRN -0.05

Regeneron Pharmaceuticals, Inc. Peer Comparison

Cookies